Greater control over speed, dose volume and quantification of delivered dose to the lungs enable researchers to explore new questions.
This article reviews how researchers have used preclinical pulmonary drug delivery methods, in particular, intratracheal aerosol technologies, to make in vivo, ex vivo and in vitro pulmonary research more clinically relevant, effective and innovative. Multiple examples of research are also included.